Skip to main content

Advertisement

SpringerLink
Log in

Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue

  • General Gynecology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

A Correction to this article was published on 08 June 2018

This article has been updated

Abstract

Purpose

The nuclear hormone receptor estrogen receptor α (ERα) is pivotal for numerous processes in the cell. As a transcription factor, it regulates eukaryotic gene expression and affects cellular proliferation and differentiation in target tissues. Moreover, ERα is known for its influence on various gynecological diseases and carcinogenesis. Since its expression is often altered in diseased tissues and this alteration was found to be caused by hypermethylation of the ESR1 promotor region in cancer, including breast and colorectal cancer, the aim of this study is to elucidate if the expression of ERα is also regulated epigenetically in endometriosis and endometrial cancer.

Methods

Using real-time methylation-specific PCR (rt-MSP), we examined endometrial and endometriotic tissues as well as five endometrial cancer cell lines and compared the methylation status with the actual expression of ERα.

Results

The results of our study indicate that, though its expression is altered in endometrial and endometriotic tissue, ERα is not regulated by methylation of the promotor region in endometriosis. In contrast, three of the five endometrial cancer cell lines are methylated in the promotor region of ESR1.

Conclusions

Thus, further investigation of the connection between ERα and endometrial cancer will be the next step.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Change history

  • 08 June 2018

    In the original publication of the article, the name of first author was misspelled. The correct name has been copied below:

References

  1. Ali SH, O’donnell AL, Mohamed S et al (2004) Overexpression of estrogen receptor-alpha in the endometrial carcinoma cell line Ishikawa: inhibition of growth and angiogenic factors. Gynecol Oncol 95:637–645

    Article  PubMed  CAS  Google Scholar 

  2. Berger U, Mcclelland RA, Wilson P et al (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Can Res 51:239–244

    CAS  Google Scholar 

  3. Bloski T, Pierson R (2008) Endometriosis and chronic pelvic pain: unraveling the mystery behind this complex condition. Nurs Women’s Health 12:382–395

    Article  Google Scholar 

  4. Bopp B, Shoupe D (1993) Luteal phase defects. J Reprod Med 38:348–356

    PubMed  CAS  Google Scholar 

  5. Cunha-Filho JS, Gross JL, Bastos De Souza CA et al (2003) Physiopathological aspects of corpus luteum defect in infertile patients with mild/minimal endometriosis. J Assist Reprod Genet 20:117–121

    Article  PubMed  PubMed Central  Google Scholar 

  6. Eads CA, Lord RV, Kurumboor SK et al (2000) Fields of aberrant CpG island hypermethylation in Barrett’s esophagus and associated adenocarcinoma. Can Res 60:5021–5026

    CAS  Google Scholar 

  7. Eeckhoute J, Keeton EK, Lupien M et al (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Can Res 67:6477–6483

    Article  CAS  Google Scholar 

  8. Elledge RM, Green S, Pugh R et al (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89:111–117

    Article  PubMed  CAS  Google Scholar 

  9. Engemise SL, Willets JM, Taylor AH et al (2011) Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system. Eur J Obstet Gynecol Reprod Biol 157:101–106

    Article  PubMed  CAS  Google Scholar 

  10. Esteller M, Corn PG, Baylin SB et al (2001) A gene hypermethylation profile of human cancer. Can Res 61:3225–3229

    CAS  Google Scholar 

  11. Harder J, Engelstaedter V, Usadel H et al (2009) CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. Br J Cancer 100:360–365

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Holmes KA, Song JS, Liu XS et al (2008) Nk3–1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. Can Res 68:7380–7385

    Article  CAS  Google Scholar 

  13. Holst F, Hoivik EA, Gibson WJ et al (2016) Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep 6:25521

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Hua S, Kittler R, White KP (2009) Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137:1259–1271

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hurtado A, Holmes KA, Geistlinger TR et al (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663–666

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Issa JP, Ottaviano YL, Celano P et al (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7:536–540

    Article  PubMed  CAS  Google Scholar 

  17. Issa JP, Zehnbauer BA, Civin CI et al (1996) The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Can Res 56:973–977

    CAS  Google Scholar 

  18. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  19. Jongen V, Briet J, De Jong R et al (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112:537–542

    Article  PubMed  CAS  Google Scholar 

  20. Kanwal R, Gupta S (2012) Epigenetic modifications in cancer. Clin Genet 81:303–311

    Article  PubMed  CAS  Google Scholar 

  21. Kokka F, Brockbank E, Oram D et al (2010) Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.CD007926.pub2

  22. Lapidus RG, Ferguson AT, Ottaviano YL et al (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res Off J Am Assoc Cancer Res 2:805–810

    CAS  Google Scholar 

  23. Lapidus RG, Nass SJ, Butash KA et al (1998) Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Can Res 58:2515–2519

    CAS  Google Scholar 

  24. Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mamm Gland Biol Neoplasia 3:85–94

    Article  CAS  Google Scholar 

  25. Li Q, Seo JH, Stranger B et al (2013) Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152:633–641

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Liu X, Shi H (2015) Regulation of estrogen receptor α expression in the hypothalamus by sex steroids: implication in the regulation of energy homeostasis. Int J Endocrinol 2015:949085

    PubMed  PubMed Central  Google Scholar 

  27. Matorras R, Rodriguez F, Perez C et al (1996) Infertile women with and without endometriosis: a case control study of luteal phase and other infertility conditions. Acta Obstet Gynecol Scand 75:826–831

    Article  PubMed  CAS  Google Scholar 

  28. Moeloek FA, Moegny E (1993) Endometriosis and luteal phase defect. Asia Ocean J Obstetr Gynaecol 19:171–176

    Article  CAS  Google Scholar 

  29. Pandya KJ, Yeap BY, Weiner LM et al (2001) Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 24:43–46

    Article  PubMed  CAS  Google Scholar 

  30. Rendina GM, Donadio C, Fabri M et al (1984) Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 17:285–291

    Article  PubMed  CAS  Google Scholar 

  31. Rogers PA, D’hooghe TM, Fazleabas A et al (2009) Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci (Thousand Oaks, Calif) 16:335–346

    Article  Google Scholar 

  32. Ross-Innes CS, Stark R, Holmes KA et al (2010) Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev 24:171–182

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Thigpen T, Brady MF, Homesley HD et al (2001) Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 19:364–367

    Article  PubMed  CAS  Google Scholar 

  34. Yue W, Yager JD, Wang JP et al (2013) Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids 78:161–170

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Munich, Germany

    Vanessa Toderow, Martina Rahmeh, Simone Hofmann, Sven Mahner, Udo Jeschke & Viktoria von Schönfeldt

  2. Klinik und Poliklinik für Frauenheilkunde, Universitätsklinikum Köln, Cologne, Germany

    Verena Kirn

  3. Department of Obstetrics and Gynecology, Ludwig-Maximilians-University, Maistrasse 11, 80377, Munich, Germany

    Udo Jeschke

Authors
  1. Vanessa Toderow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martina Rahmeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simone Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Verena Kirn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sven Mahner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Udo Jeschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Viktoria von Schönfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

VT: Performed the experiments, wrote the first draft of the manuscript. MR: Performed the experiments, supervised the methodology. SH: Performed the experiments, supervised the methodology. VK: Developed the Methodology of the methylation analyses. SM: Organized and Supervised Funding and final manuscript preparation. UJ: Supervised the Methodology and the final draft of the manuscript. VvS: Development of the project idea, principal supervision of the investigators.

Corresponding author

Correspondence to Udo Jeschke.

Ethics declarations

Funding

This study was funded by the Medical Faculty of the Ludwig Maximilians University of Munich.

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toderow, V., Rahmeh, M., Hofmann, S. et al. Promotor analysis of ESR1 in endometrial cancer cell lines, endometrial and endometriotic tissue. Arch Gynecol Obstet 296, 269–276 (2017). https://doi.org/10.1007/s00404-017-4405-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-017-4405-x

Keywords

Search

Navigation